Opko Acquires CLIA Lab | GenomeWeb

NEW YORK (GenomeWeb News) – Opko Health has acquired Prost-Data, a Nashville, Tenn.-based CLIA laboratory doing business under the name OURLab.

Opko said that the acquisition would provide it with a commercial platform to support the US commercial launch of its 4Kscore protein biomarker prostate cancer test. The 4kscore test employs two protein biomarkers in the kallikrein family along with prostate-specific antigen for early detection of prostate cancer.

The lab has 18 phlebotomy sites throughout the US and a national sales force calling on urologists.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Rules and regulations governing genetic modifications of human embryos vary from country to country, Nature News says, but such work may take place despite restrictions.

Ancestry.com is eyeing an expansion into genomic risk assessments, the Verge reports.

In PNAS this week: adzuki bean genome, spontaneous mutation patterns in E. coli, and more.

An op-ed in the New York Times discusses banking of fecal samples to restore the gut microbiome.